Chinese scientists have developed a new COVID-19 vaccine that has shown 92% efficacy in phase 3 clinical trials, according to a study published in the journal The Lancet. The vaccine, known as ZF2001, is a recombinant protein subunit vaccine that targets the spike protein of the SARS-CoV-2 virus. It was developed by Anhui Zhifei Longcom Biopharmaceutical Co., Ltd..
The phase 3 clinical trial was conducted in Uzbekistan and involved over 13,000 participants. The participants were randomly assigned to receive two doses of ZF2001 or a placebo. The results showed that the vaccine was 92% effective in preventing symptomatic COVID-19 infection. The vaccine was also well-tolerated, with the most common side effects being injection site pain, fever, and fatigue..
The development of ZF2001 is a significant milestone in the fight against COVID-19. The vaccine is the first recombinant protein subunit vaccine to show such high efficacy in phase 3 clinical trials. It is also the first COVID-19 vaccine to be developed in China..
ZF2001 is expected to play an important role in the global fight against COVID-19. The vaccine is easy to produce and store, and it is likely to be affordable for low- and middle-income countries. It is also expected to be effective against new variants of the SARS-CoV-2 virus..
The development of ZF2001 is a testament to the scientific capabilities of Chinese scientists. It is also a sign of the growing role that China is playing in the global fight against COVID-19..
